Validation of the Khorana Score in Acute Myeloid Leukemia Patients: A Single Institution Experience

作者：Sayeef Mirza, Sayeef Mirza, Seongseok Yun, Najla Al Ali, Maher Elharake, Nathan Visweshwar, Daniel P. Schwartz, Katherine Robinson, Ethan Nowell, Grace Engle, Ibraahim Badat, Thomas Brimer, Amra Kuc, Ashton Sequeira, Sabbir Mirza, Sabbir Mirza, Dhiraj Sikaria, Jesus Diaz Vera, Noah Hackney, Rami S. Komrokji, Michael Jaglal · 发表于：Blood · 年份：2018 · DOI：10.1182/blood-2018-99-117545 · 被引用次数：1 · 研究领域：Myeloproliferative Neoplasms: Diagnosis and Treatment、Hematological disorders and diagnostics、Acute Myeloid Leukemia Research

Abstract INTRODUCTION: Both solid and hematologic malignancies are associated with an increased risk of thromboembolic events, according to previous studies. One of the most common risk scoring systems was developed based on type of non-hematologic cancer, body mass index (BMI), WBC, hemoglobin, and platelet counts. However, compared to other solid tumors, acute leukemia patients commonly present with pancytopenia at the time of diagnosis and the Khorana Risk Score (KRS) has not been validated in patients with acute myeloid leukemia (AML). The goal of our study was to validate the KRS in AML patients. METHODS: Using Total Cancer Care (TCC), we retrospectively identified histologically confirmed AML patients from 2000 to 2018. Clinical and laboratory variables including age, gender, previous cancer history, use of growth factors, underlying coagulopathy, white blood cell counts, hemoglobin, and platelet counts were characterized at the time of AML diagnosis and annotated using descriptive statistics. The thrombotic event rate was estimated with the Kaplan-Meier method and compared using log-rank test. All statistical analyses were performed using SPSS v24.0 and GraphPad Prism 7. RESULTS: A total of 867 AML patients were included in this study. The median age at AML diagnosis was 75 (51-96) years and male patients were 65% (n=565). A total of 28% (n=241) patients had prior cancer history (hematologic malignancies, n=34; solid tumor, n=207). A total of 12% (n=101), 7% (n=58), an...